The currently “great unanswered” question in the management of advanced prostate cancer is the order of agents to be used in the treatment of men who are receiving first-line therapy for metastatic prostate cancer after it becomes castration-resistant. What we are going to need will be data from head-to-head trials. In the interim, what we […]
↧